Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03456076




Registration number
NCT03456076
Ethics application status
Date submitted
6/03/2018
Date registered
7/03/2018
Date last updated
26/08/2024

Titles & IDs
Public title
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
Scientific title
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer
Secondary ID [1] 0 0
2017-004331-37
Secondary ID [2] 0 0
BO40336
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Carcinoma, Non-Small-Cell Lung 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Non small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Alectnib
Treatment: Drugs - Cisplatin
Treatment: Drugs - Vinorelbine
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Pemetrexed
Treatment: Drugs - Carboplatin

Experimental: Alectinib -

Active comparator: Platinum-Based Chemotherapy -


Treatment: Drugs: Alectnib
Participants will receive alectinib 600 mg orally BID until completion of treatment period (24 months) or recurrence of disease , unacceptable toxicity, withdrawal of consent or death, whichever occurs first.

Treatment: Drugs: Cisplatin
Participants will receive Cisplatin 75 milligrams per square meter (mg/m\^2) on Day 1 every 21 days IV intravenously (IV) until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."

Treatment: Drugs: Vinorelbine
Participants will receive Vinorelbine 25 mg/m\^2 IV on Days 1 and 8 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.

Treatment: Drugs: Gemcitabine
Participants will receive Gemcitabine 1250 mg/m\^2 on Days 1 and 8 Q21D IV until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first.

Treatment: Drugs: Pemetrexed
Participants will receive 500 mg/m\^2 Day 1 Q21D until completion of treatment period (4 cycles), recurrence of disease, unacceptable toxicity, withdrawal of consent, or death, whichever occurs first."

Treatment: Drugs: Carboplatin
For participants who experience unacceptable toxicity with cisplatin, carboplatin can be used.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Disease-free Survival (DFS), as Assessed by the Investigator
Timepoint [1] 0 0
Approximately 58 months
Secondary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
From the date of randomization until death due to any cause up to approximately 8 years
Secondary outcome [2] 0 0
Percentage of Participants With Adverse Events (AEs)
Timepoint [2] 0 0
Until 28 days after the last dose of alectinib (up to 2 years) or 28 days after end of last cycle of chemotherapy (up to 4 cycles)
Secondary outcome [3] 0 0
AEs Grade 3-5 With a Difference in Incidence Rate of at Least 2% Between Treatment Arms
Timepoint [3] 0 0
Until 28 days after the last dose of alectinib (up to 2 years) or 28 days after end of last cycle of chemotherapy (up to 4 cycles)
Secondary outcome [4] 0 0
Plasma Concentration of Alectinib
Timepoint [4] 0 0
Predose (2 hours) Week 3 - Week 96
Secondary outcome [5] 0 0
Plasma Concentration of Alectinib Metabolite M4
Timepoint [5] 0 0
Predose (2 hours) Week 3 - Week 96

Eligibility
Key inclusion criteria
Key Inclusion Criteria

* Age =18 years
* Complete resection of histologically confirmed Stage IB (tumor = 4 cm) to Stage IIIA (T2-3 N0, T1-3 N1, T1-3 N2, T4 N0-1) NSCLC as per Union Internationale Contre le Cancer / American Joint Committee on Cancer, 7th edition, with negative margins, at 4-12 weeks before enrollment
* If mediastinoscopy was not performed preoperatively, it is expected that, at a minimum, mediastinal lymph node systematic sampling will have occurred
* Documented ALK-positive disease according to an FDA-approved and CE-marked test
* Eligible to receive a platinum-based chemotherapy regimen according to the local labels or guidelines
* Eastern Cooperative Oncology Group Performance Status of Grade 0 or 1
* Adequate hematologic and renal function
* For women of childbearing potential: agreement to remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 90 days after the last dose of alectinib or according to local labels or guidelines for chemotherapy
* For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm for at least 90 days after the last dose of alectinib or according to local labels or guidelines for chemotherapy. Men must refrain from donating sperm during this same period
* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Exclusion Criteria

* Pregnant or breastfeeding, or intending to become pregnant during the study or within 90 days after the last dose of alectinib or according to local labels or guidelines for chemotherapy
* Prior adjuvant radiotherapy for NSCLC
* Prior exposure to systemic anti-cancer therapy and ALK inhibitors
* Stage IIIA N2 patients that, in the investigator's opinion, should receive post-operative radiotherapy treatment are excluded from the study
* Known sensitivity to any component of study drug to which the patient may be randomized. This includes, but is not limited to, patients with galactose intolerance, a congenital lactase deficiency or glucose-galactose malabsorption.
* Malignancies other than NSCLC within 5 years prior to enrollment, except for curatively treated basal cell carcinoma of the skin, early gastrointestinal (GI) cancer by endoscopic resection, in situ carcinoma of the cervix, ductal carcinoma in situ, papillary thyroid cancer, or any cured cancer that is considered to have no impact on disease free survival or overall survival for the current NSCLC
* Any GI disorder that may affect absorption of oral medications, such as malabsorption syndrome or status post-major bowel resection
* Liver disease characterized by aspartate transaminase and alanine transaminase >= 3 × upper limit of normal or impaired excretory function or synthetic function or other conditions of decompensated liver disease such as coagulopathy, hepatic encephalopathy, hypoalbuminemia, ascites, or bleeding from esophageal varices or active viral or active autoimmune, alcoholic, or other types of acute hepatitis
* Japanese patients participating in the serial/intensive PK sample collection only: administration of strong/potent CYP450 3A inhibitors or inducers within 14 days prior to the first dose of study treatment and while on treatment with alectinib up to Week 3
* Any exclusion criteria based on the local labels or guidelines for chemotherapy regimen
* Patients with symptomatic bradycardia
* History of organ transplant
* Known HIV positivity or AIDS-related illness
* Any clinically significant concomitant disease or condition that could interfere with-or for which the treatment might interfere with the conduct of the study or the absorption of oral medications or that would pose an unacceptable risk to the patients in this study, in the opinion of the Principal Investigator
* Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
16/08/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
19/11/2026
Actual
Sample size
Target
Accrual to date
Final
257
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Chris O'Brien Lifehouse - Camperdown
Recruitment hospital [2] 0 0
Northern Cancer Institute - St Leonards
Recruitment hospital [3] 0 0
Peter MacCallum Cancer Center - North Melbourne
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2065 - St Leonards
Recruitment postcode(s) [3] 0 0
3051 - North Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Illinois
Country [2] 0 0
United States of America
State/province [2] 0 0
Massachusetts
Country [3] 0 0
United States of America
State/province [3] 0 0
Pennsylvania
Country [4] 0 0
Austria
State/province [4] 0 0
Wien
Country [5] 0 0
Belarus
State/province [5] 0 0
Homyel'skaya Voblasts'
Country [6] 0 0
Belarus
State/province [6] 0 0
Hrodzyenskaya Voblasts'
Country [7] 0 0
Belarus
State/province [7] 0 0
Vitsyebskaya Voblasts'
Country [8] 0 0
Bosnia and Herzegovina
State/province [8] 0 0
Sarajevo
Country [9] 0 0
China
State/province [9] 0 0
Beijing
Country [10] 0 0
China
State/province [10] 0 0
Changchun
Country [11] 0 0
China
State/province [11] 0 0
Chengdu
Country [12] 0 0
China
State/province [12] 0 0
Fuzhou City
Country [13] 0 0
China
State/province [13] 0 0
Guangzhou
Country [14] 0 0
China
State/province [14] 0 0
Jinan
Country [15] 0 0
China
State/province [15] 0 0
Shanghai
Country [16] 0 0
China
State/province [16] 0 0
Shenzhen
Country [17] 0 0
China
State/province [17] 0 0
Wuhan City
Country [18] 0 0
China
State/province [18] 0 0
Xi'an
Country [19] 0 0
China
State/province [19] 0 0
Zhejiang
Country [20] 0 0
Denmark
State/province [20] 0 0
Odense C
Country [21] 0 0
Egypt
State/province [21] 0 0
Cairo
Country [22] 0 0
France
State/province [22] 0 0
Angers
Country [23] 0 0
France
State/province [23] 0 0
Marseille
Country [24] 0 0
France
State/province [24] 0 0
Montpellier
Country [25] 0 0
France
State/province [25] 0 0
Paris
Country [26] 0 0
France
State/province [26] 0 0
St Quentin
Country [27] 0 0
France
State/province [27] 0 0
Toulon
Country [28] 0 0
France
State/province [28] 0 0
Villejuif cedex
Country [29] 0 0
Germany
State/province [29] 0 0
Chemnitz
Country [30] 0 0
Germany
State/province [30] 0 0
Georgsmarienhütte
Country [31] 0 0
Germany
State/province [31] 0 0
Heidelberg
Country [32] 0 0
Germany
State/province [32] 0 0
Immenhausen
Country [33] 0 0
Greece
State/province [33] 0 0
Athens
Country [34] 0 0
Greece
State/province [34] 0 0
Thessaloniki
Country [35] 0 0
Hungary
State/province [35] 0 0
Budapest
Country [36] 0 0
Hungary
State/province [36] 0 0
Pecs
Country [37] 0 0
Hungary
State/province [37] 0 0
Szolnok
Country [38] 0 0
Israel
State/province [38] 0 0
Haifa
Country [39] 0 0
Israel
State/province [39] 0 0
Kfar- Saba
Country [40] 0 0
Italy
State/province [40] 0 0
Campania
Country [41] 0 0
Italy
State/province [41] 0 0
Emilia-Romagna
Country [42] 0 0
Italy
State/province [42] 0 0
Friuli-Venezia Giulia
Country [43] 0 0
Italy
State/province [43] 0 0
Lazio
Country [44] 0 0
Italy
State/province [44] 0 0
Lombardia
Country [45] 0 0
Italy
State/province [45] 0 0
Piemonte
Country [46] 0 0
Italy
State/province [46] 0 0
Toscana
Country [47] 0 0
Italy
State/province [47] 0 0
Umbria
Country [48] 0 0
Japan
State/province [48] 0 0
Aichi
Country [49] 0 0
Japan
State/province [49] 0 0
Chiba
Country [50] 0 0
Japan
State/province [50] 0 0
Fukuoka
Country [51] 0 0
Japan
State/province [51] 0 0
Hiroshima
Country [52] 0 0
Japan
State/province [52] 0 0
Hokkaido
Country [53] 0 0
Japan
State/province [53] 0 0
Hyogo
Country [54] 0 0
Japan
State/province [54] 0 0
Kanagawa
Country [55] 0 0
Japan
State/province [55] 0 0
Kumamoto
Country [56] 0 0
Japan
State/province [56] 0 0
Kyoto
Country [57] 0 0
Japan
State/province [57] 0 0
Miyagi
Country [58] 0 0
Japan
State/province [58] 0 0
Niigata
Country [59] 0 0
Japan
State/province [59] 0 0
Okayama
Country [60] 0 0
Japan
State/province [60] 0 0
Osaka
Country [61] 0 0
Japan
State/province [61] 0 0
Shizuoka
Country [62] 0 0
Japan
State/province [62] 0 0
Tokyo
Country [63] 0 0
Kazakhstan
State/province [63] 0 0
Almaty
Country [64] 0 0
Korea, Republic of
State/province [64] 0 0
Goyang-si
Country [65] 0 0
Korea, Republic of
State/province [65] 0 0
Gyeonggi-do
Country [66] 0 0
Korea, Republic of
State/province [66] 0 0
Incheon
Country [67] 0 0
Korea, Republic of
State/province [67] 0 0
Jeollanam-do
Country [68] 0 0
Korea, Republic of
State/province [68] 0 0
Seongnam-si
Country [69] 0 0
Korea, Republic of
State/province [69] 0 0
Seoul
Country [70] 0 0
North Macedonia
State/province [70] 0 0
Skopje
Country [71] 0 0
Poland
State/province [71] 0 0
Gda?sk
Country [72] 0 0
Poland
State/province [72] 0 0
Kraków
Country [73] 0 0
Poland
State/province [73] 0 0
Olsztyn
Country [74] 0 0
Poland
State/province [74] 0 0
Poznan
Country [75] 0 0
Poland
State/province [75] 0 0
Warszawa
Country [76] 0 0
Poland
State/province [76] 0 0
Wroc?aw
Country [77] 0 0
Romania
State/province [77] 0 0
Cluj-Napoca
Country [78] 0 0
Romania
State/province [78] 0 0
Cluj-napoca
Country [79] 0 0
Romania
State/province [79] 0 0
Timisoara
Country [80] 0 0
Russian Federation
State/province [80] 0 0
Moskovskaja Oblast
Country [81] 0 0
Russian Federation
State/province [81] 0 0
Sankt Petersburg
Country [82] 0 0
Russian Federation
State/province [82] 0 0
Krasnodar
Country [83] 0 0
Spain
State/province [83] 0 0
Barcelona
Country [84] 0 0
Spain
State/province [84] 0 0
Guipuzcoa
Country [85] 0 0
Spain
State/province [85] 0 0
Madrid
Country [86] 0 0
Spain
State/province [86] 0 0
La Coruña
Country [87] 0 0
Spain
State/province [87] 0 0
Malaga
Country [88] 0 0
Spain
State/province [88] 0 0
Sevilla
Country [89] 0 0
Spain
State/province [89] 0 0
Valencia
Country [90] 0 0
Taiwan
State/province [90] 0 0
Kaohsiung
Country [91] 0 0
Taiwan
State/province [91] 0 0
Taichung
Country [92] 0 0
Taiwan
State/province [92] 0 0
Taipei
Country [93] 0 0
Taiwan
State/province [93] 0 0
Taoyuan
Country [94] 0 0
Taiwan
State/province [94] 0 0
Xitun Dist.
Country [95] 0 0
Thailand
State/province [95] 0 0
Bangkok
Country [96] 0 0
Turkey
State/province [96] 0 0
Adana
Country [97] 0 0
Turkey
State/province [97] 0 0
Ankara
Country [98] 0 0
Turkey
State/province [98] 0 0
Istanbul
Country [99] 0 0
Turkey
State/province [99] 0 0
Izmir
Country [100] 0 0
Turkey
State/province [100] 0 0
Malatya
Country [101] 0 0
Turkey
State/province [101] 0 0
Samsun
Country [102] 0 0
Turkey
State/province [102] 0 0
Sihhiye/Ankara
Country [103] 0 0
Ukraine
State/province [103] 0 0
KIEV Governorate
Country [104] 0 0
Ukraine
State/province [104] 0 0
Dnipropetrovsk
Country [105] 0 0
Ukraine
State/province [105] 0 0
Kyiv
Country [106] 0 0
Ukraine
State/province [106] 0 0
Sumy
Country [107] 0 0
Ukraine
State/province [107] 0 0
Vinnytsia
Country [108] 0 0
United Kingdom
State/province [108] 0 0
London
Country [109] 0 0
United Kingdom
State/province [109] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Hoffmann-La Roche
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03456076